Clin Endosc.  2018 Sep;51(5):430-438. 10.5946/ce.2018.148.

Training in Bariatric and Metabolic Endoscopic Therapies

• Jirapinyo
• Thompson C

• KMID: 2427716
• DOI: http://doi.org/10.5946/ce.2018.148

Abstract

Bariatric endoscopy is an emerging subspecialty for gastroenterologists encompassing a broad array of procedures including primary endoscopic bariatric and metabolic therapies and the treatment of complications of bariatric surgery. In addition, comprehensive understanding of lifestyle intervention and pharmacotherapy are essential to successful outcomes. This review summarizes goals and steps of training for this emerging field.

Keyword

Endoscopic bariatric and metabolic therapies; EBMT; Bariatric; Metabolic; Training

MeSH Terms

Bariatric Surgery
Drug Therapy
Endoscopy
Life Style

Figure

• 

  Fig. 1. Primary endoscopic bariatric and metabolic therapies. (A) OrberaTM Balloon. (B) ReShapeTM Balloon. (C) ObalonTM Balloon. (D) Endoscopic Sutured Gastroplasty. (E) Primary Obesity Surgery Endoluminal. (F) Aspiration Therapy. Adapted from Jirapinyo et al., with permission from Elsevier [21].

• 

  Fig. 2. Overstitch Endoscopic Suturing System. (A) The handle open corresponds to (D). (B) The handle being closed corresponds to (E). (C) Fully closed handle with anchor exchange catheter (pick-up) being advanced to remove the needle from the curved suture arm. This corresponds to (F). (D) The needle and suture loaded on the curved suture arm in a fully open configuration. (E) The needle and suture on the curved suture arm as it would appear being advanced through tissue. (F) The curved suture arm in a closed configuration.

• 

  Fig. 3. The Incisionless Operating Platform System. (A) Transport. (B) G-Prox. (C) G-Cath. (D) G-Lix.

• 

  Fig. 4. An Endoscopic Suturing Simulator.

Reference

1. World Health Organization. Obesity and overweight [Internet]. Geneva: WHO;c2018. [updated 2018 Feb 16; cited 2018 Jun 29]. Available from: http://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight.

2. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol. 2014; 63(25 Pt B):2985–3023.

3. Look AHEAD Research Group. Eight-year weight losses with an intensive lifestyle intervention: the look AHEAD study. Obesity (Silver Spring). 2014; 22:5–13.

4. Igel LI, Kumar RB, Saunders KH, Aronne LJ. Practical use of pharmacotherapy for obesity. Gastroenterology. 2017; 152:1765–1779.

5. Corcelles R, Boules M, Froylich D, et al. Total weight loss as the outcome measure of choice after Roux-en-Y gastric bypass. Obes Surg. 2016; 26:1794–1798.

6. Ponce J, Nguyen NT, Hutter M, Sudan R, Morton JM. American Society for Metabolic and Bariatric Surgery estimation of bariatric surgery procedures in the United States, 2011-2014. Surg Obes Relat Dis. 2015; 11:1199–1200.

7. Abu Dayyeh BK, Eaton LL, Woodman G, et al. A randomized, multi-center study to evaluate the safety and effectiveness of an intragastric balloon as an adjunct to a behavioral modification program, in comparison with a behavioral modification program alone in the weight management of obese subjects. Gastrointest Endosc. 2015; 81(5 Suppl):AB147.

8. Ponce J, Woodman G, Swain J, et al. The REDUCE pivotal trial: a prospective, randomized controlled pivotal trial of a dual intragastric balloon for the treatment of obesity. Surg Obes Relat Dis. 2015; 11:874–881.

9. Sullivan S, Swain JM, Woodman G, et al. The obalon swallowable 6-month balloon system is more effective than moderate intensity lifestyle therapy alone: results from a 6- month randomized sham controlled trial. Gastroenterology. 2016; 150(4 Suppl):S1267.

10. US Food and Drug Administration. Summary of safety and effectiveness data (SSED): ORBERA™ intragastric balloon system [Internet]. Silver Spring (MD): FDA;c2015. [updated 2015 Aug 5; cited 2018 Sep 19]. Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf14/P140008b.pdf.

11. US Food and Drug Administration. Summary of safety and effectiveness data (SSED): obalon balloon system [Internet]. Silver Spring (MD): FDA;c2016. [updated 2016 Sep 8; cited 2018 Sep 19]. Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf16/P160001b.pdf.

12. US Food and Drug Administration. Summary of safety and effectiveness data (SSED): ReShape™ integrated dual balloon system [Internet]. Silver Spring (MD): FDA;c2015. [updated 2015 Jul 28; cited 2018 Sep 19]. Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf14/P140012b.pdf.

13. Jirapinyo P, Slattery J, Ryan MB, Abu Dayyeh BK, Lautz DB, Thompson CC. Evaluation of an endoscopic suturing device for transoral outlet reduction in patients with weight regain following Roux-en-Y gastric bypass. Endoscopy. 2013; 45:532–536.

14. Sharaiha RZ, Kedia P, Kumta N, et al. Initial experience with endoscopic sleeve gastroplasty: technical success and reproducibility in the bariatric population. Endoscopy. 2015; 47:164–166.

15. Kumar N, Thompson CC. Transoral outlet reduction for weight regain after gastric bypass: long-term follow-up. Gastrointest Endosc. 2016; 83:776–779.

16. Lopez-Nava G, Galvao M, Bautista-Castaño I, Fernandez-Corbelle JP, Trell M. Endoscopic sleeve gastroplasty with 1-year follow-up: factors predictive of success. Endosc Int Open. 2016; 4:E222–E227.

17. Lopez-Nava G, Sharaiha RZ, Vargas EJ, et al. Endoscopic sleeve gastroplasty for obesity: a multicenter study of 248 patients with 24 months follow-up. Obes Surg. 2017; 27:2649–2655.

18. Miller K, Turró R, Greve JW, Bakker CM, Buchwald JN, Espinós JC. MILEPOST multicenter randomized controlled trial: 12-month weight loss and satiety outcomes after pose (SM) vs. medical therapy. Obes Surg. 2017; 27:310–322.

19. López-Nava G, Bautista-Castaño I, Jimenez A, de Grado T, Fernandez-Corbelle JP. The primary obesity surgery endolumenal (POSE) procedure: one-year patient weight loss and safety outcomes. Surg Obes Relat Dis. 2015; 11:861–865.

20. Thompson CC, Abu Dayyeh BK, Kushner R, et al. Percutaneous gastrostomy device for the treatment of class II and class III obesity: results of a randomized controlled trial. Am J Gastroenterol. 2017; 112:447–457.

21. Jirapinyo P, Thompson CC. Endoscopic bariatric and metabolic therapies: surgical analogues and mechanisms of action. Clin Gastroenterol Hepatol. 2017; 15:619–630.

22. Foxx-Orenstein AE. Gastrointestinal symptoms and diseases related to obesity: an overview. Gastroenterol Clin North Am. 2010; 39:23–37.

23. Camilleri M, Malhi H, Acosta A. Gastrointestinal complications of obesity. Gastroenterology. 2017; 152:1656–1670.

24. Jirapinyo P, Kumar N, Thompson CC. Patients with Roux-en-Y gastric bypass require increased sedation during upper endoscopy. Clin Gastroenterol Hepatol. 2015; 13:1432–1436.

25. ASGE/ASMBS Task Force on Endoscopic Bariatric Therapy. A pathway to endoscopic bariatric therapies. Surg Obes Relat Dis. 2011; 7:672–682.

26. Sullivan S, Edmundowicz SA, Thompson CC. Endoscopic bariatric and metabolic therapies: new and emerging technologies. Gastroenterology. 2017; 152:1791–1801.

27. Kushner RF, Brittan D, Cleek J, et al. The American board of obesity medicine: five-year report. Obesity (Silver Spring). 2017; 25:982–984.

28. Patel LY, Lapin B, Brown CS, et al. Outcomes following 50 consecutive endoscopic gastrojejunal revisions for weight gain following Roux-en-Y gastric bypass: a comparison of endoscopic suturing techniques for stoma reduction. Surg Endosc. 2017; 31:2667–2677.

29. Jirapinyo P, Kröner PT, Thompson CC. Purse-string transoral outlet reduction (TORe) is effective at inducing weight loss and improvement in metabolic comorbidities after Roux-en-Y gastric bypass. Endoscopy. 2018; 50:371–377.

30. Schulman AR, Kumar N, Thompson CC. Transoral outlet reduction: a comparison of purse-string with interrupted stitch technique. Gastrointest Endosc. 2018; 87:1222–1228.

31. Jirapinyo P, Kumar N, Thompson CC. Endoscopic suturing: indications, procedural complexity and learning curve. Gastrointest Endosc. 2016; 83(5 Suppl):AB494–AB495.

32. Skinner MJ, Aihara H, Jirapinyo P, Thompson CC. Development and initial validation of a fully synthetic and reusable endoscopic suturing simulator. Gastrointest Endosc. 2017; 85(5 Suppl):AB502–AB503.

33. Acosta A, Streett S, Kroh MD, et al. White paper AGA: POWER - practice guide on obesity and weight management, education, and resources. Clin Gastroenterol Hepatol. 2017; 15:631–649. e10.

34. ASGE Bariatric Endoscopy Task Force and ASGE Technology Committee, Abu Dayyeh BK, Kumar N, et al. ASGE bariatric endoscopy task force systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting endoscopic bariatric therapies. Gastrointest Endosc. 2015; 82:425–438. e5.

35. Berthoud HR, Klein S. Advances in obesity: causes, consequences, and therapy. Gastroenterology. 2017; 152:1635–1637.